Slide 1: Corporate Presentation December 2022
Exhibit 99.1 Corporate Presentation December 2022 NASDAQ: CFRX
Slide 2: Forward Looking Statements/Disclaimer
Forward Looking Statements/Disclaimer This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “wi
Slide 3: The Burden of Bacterial Antimicrobial Resistance
The Burden of Bacterial Antimicrobial Resistance Deaths by Resistant Pathogen There remains an urgent Deaths by need for alternatives that will Infection Type circumvent bacterial resistance to current medicines Antibacterial innovation stems from small, emerging biotechnology companies Sources:(1)
Slide 4: About ContraFect
About ContraFect ContraFect is a clinical-stage biotechnology company leading the development of direct lytic agents (DLAs), which include lysins and amurin peptides, as new medical modalities for the treatment of life-threatening and antibiotic-resistant infections
Slide 5: Senior Leadership
Senior Leadership Roger Pomerantz, MD, FACP – CEO Michael Messinger– CFO Garrett Nichols – Interim CMO Natalie Bogdanos – General Counsel Ray Schuch– VP of Research Gary Woodnutt – SVP of Translational 5
Slide 6: Board of Directors
Board of Directors Roger Pomerantz, MD, FACP – Chair Lishan Aklog, MD David Low Former Chairman and CEO, Investment Banker at MTS CEO of Seres PAVmed Formerly at Lazard, JP Morgan, Lehman Sol Barer, PhD – Lead Independent Jane F. Barlow, MD, MPH Michael Otto, PhD EVP & CCO, Real Endpoints Former Cha
Slide 7: Medical Paradigm Shifts in Standard-of-Care
Medical Paradigm Shifts in Standard-of-Care PRIOR TREATMENT NEW TREATMENT Cancer Immunotherapies Chemotherapy No treatments Gene therapies Congenital Disorders available Potential Therapies Superiority Mortality benefits Microbiome Anti-Infectives Positive health Direct lytic agents economics Antibi
Slide 8: Portfolio: Leading the Development of DLAs as New Medical Modalities
Portfolio LEADING THE DEVELOPMENT OF DLAs AS NEW MEDICAL MODALITIES Program Discovery Preclinical Phase 1 Phase 2 Phase 3 Prosthetic joint infections (PJI) CTA approved* Staphylococcus aureus Exebacase Staphylococcus epidermidis Staph aureus bacteremia, including endocarditis Stopped Gram-negative p
Slide 9: Exebacase (CF-301): Direct Lytic Agent for Invasive Staphylococcal Infections
Novel, First-In-Class, Direct Lytic Agent for Invasive Staphylococcal Infections, Exebacase (CF-301) Including S. aureus and S. epidermidis
Slide 10: Exebacase: Potential First-in-Class Lysin Candidate
Exebacase: Potential First-in-Class Lysin Candidate Key attributes Clinical-stage program FDA designations for Fast Track and Breakthrough 26 kDa bacterial cell wall hydrolase enzyme (1)(2) Therapy Highly potent in vitro and in vivo against S. aureus Eligible for Streamlined Development for antibact
Slide 11: Exebacase: Interim Analysis of the Phase 2 DISRUPT Study
Exebacase: Interim Analysis of the Phase 3 DISRUPT Study Superiority design study Preliminary findings of internal analysis Randomized, double-blind, placebo-controlled, conducted Unexpectedly high SOCA alone response rate in the US only, in patients with S. aureus bacteremia, Exebacase Phase 2 SOCA
Slide 12: DISRUPT: Baseline Characteristics from Adjudicated Futility Dataset
DISRUPT: Baseline Characteristics from Adjudicated Futility Dataset Exebacase + SOCA SOCA alone Patient characteristics generally well balanced (n=55) (n=29) Final diagnosis by Adjudication Committee Complicated S. aureus bloodstream infection 42 (76.4%) 20 (69.0%) Uncomplicated S. aureus bloodstrea
Slide 13: DISRUPT: Baseline Characteristics from Adjudicated Futility Dataset
DISRUPT: Baseline Characteristics from Adjudicated Futility Dataset Exebacase + SOCA SOCA alone Patient characteristics generally well balanced (n=55) (n=29) Risk factors for complicated S. aureus bloodstream infection/infective endocarditis Poorly controlled diabetes 10 (18.2%) 6 (20.7%) Injection
Slide 14: DISRUPT: Baseline Characteristics from Adjudicated Futility Dataset
DISRUPT: Baseline Characteristics from Adjudicated Futility Dataset Exebacase + SOCA SOCA alone Patient characteristics generally well balanced (n=55) (n=29) Duration of SOCA therapy prior to dosing exebacase <=24 hours 1 (1.8%) 1 (3.5%) >24-48 hours 14 (25.5%) 4 (13.8%) >48 hours 40 (72.7%) 24 (82.
Slide 15: Exebacase: Preliminary Findings from Internal Analysis
Exebacase: Preliminary Findings from Internal Analysis Extensive analysis of the preliminary data set from July 2022 All subgroup analyses, other than APACHE II score were as expected based on results of interim futility analysis Exebacase arm had imbalance of MRSA patients with extremely MRSA MSSA
Slide 16: Exebacase for Chronic Prosthetic Joint Infections (PJI)
Exebacase for Chronic Prosthetic Joint Infections (PJI) S. aureus or Coagulase-Negative Staphylococci (CoNS) ©2022 ContraFect Corporation
Slide 17: Epidemiology and Treatment of Prosthetic Joint Infections
Epidemiology and Treatment of Prosthetic Joint Infections Prosthetic joint infections Roughly 1.5 million primary TJA of the hip and knee were performed in 2014 in the US and (1) even conservative methods project this volume to increase at least 2-fold by 2030 (1) ~2% infection rate results in 65,00
Slide 18: Surgical Revision for PJI Carries a High Economic Burden
Surgical Revision for PJI Carries a High Economic Burden Projected direct cost to US hospitals of over $1.8B First year cost of periprosthetic (1) in 2030 infection with revision Average cost for revisions of infected joints is (2)(3) approximately 4x primary procedures ➢ One-stage revision averages
Slide 19: The Potency of Exebacase Against Biofilms Has Been Studied Extensively
The Potency of Exebacase Against Biofilms Has Been Studied Extensively Exebacase has demonstrated uniquely potent anti-biofilm activity across a broad range of studies In vivo models In vitro and ex vivo studies (5) Over 150 different isolates, including S. aureus, MRSA MRSA rat osteomyelitis (1)(2)
Slide 20: Exebacase Demonstrated Potency In Vitro Against CoNS Biofilms Isolated from PJIs
Exebacase Demonstrated Potency In Vitro Against CoNS Biofilms Isolated from PJIs Biomass reduction of exebacase alone and in synergy with antibiotics 20 Source: Souche et al., Hospices Civils de Lyon, Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolat
Slide 21: Exebacase Demonstrated In Vivo Potency in MRSA Implant-Associated Osteomyelitis Model
Exebacase Demonstrated In Vivo Potency in MRSA Implant-Associated Osteomyelitis Model Rabbit implant-associated osteomyelitis model Bacterial burden on implant Bacterial burden of the bone *p<0.0025 vs vehicle control **p<0.0098 vs daptomycin Exebacase as a monotherapy, or in addition to daptomycin,
Slide 22: Exebacase for PJI: Compassionate Use Summary
Exebacase for PJI: Compassionate Use Summary — Hôpital de la Croix Rousse 16 patients treated to-date with intra-articular exebacase Minimally invasive arthroscopic debridement with joint retention No adverse events have occurred during arthroscopy (2) Four patients treated in patients similar to po
Slide 23: Exebacase for PJI: Expected to Initiate Dosing in Patients in Q1 2023
Exebacase for PJI: Expected to Initiate Dosing in Patients in Q1 2023 Phase 1b/2 Study Design Approved by ANSM Randomized, placebo controlled study of intra-articular exebacase vs. placebo after arthroscopic debridement and joint retention followed by systemic antibiotics In patients with chronic pr
Slide 24: CF-370: Engineered Direct Lytic Agent Combating Gram-negative Pathogens
Novel, Engineered Direct Lytic Agent Combating Gram-negative Pathogens, CF-370 Including MDR and XDR Strains
Slide 25: CF-370 is Advancing to IND Submission in 2023
CF-370 is Advancing to IND Submission in 2023 Discovered using proprietary lysin platform First lysin engineered to bypass the outer membrane of Gram-negative (GN) bacteria and show potent activity in human blood Pre-clinical data In vitro data demonstrated potent activity against Gram-negative path
Slide 26: CF-370: Potent In Vitro Activity Against Gram-negative Pathogens
CF-370: Demonstrated Potent In Vitro Activity Against Gram-negative Pathogens Minimal inhibitory concentrations (MICs) against CDC Antibiotic Resistance Bank CF-370 can be studied in Phase 2 PoC trial for use in pulmonary exacerbations in Cystic Fibrosis (CF) patients, based on in vitro testing agai
Slide 27: CF-370: Potent In Vivo Activity in Multiple Animal Models
CF-370: Demonstrated Potent In Vivo Activity in Multiple Animal Models Activity demonstrated against P. aeruginosa, including an extensively drug-resistant strain animal models of lung infection and endocarditis, A. baumannii and K. pneumoniae in animal models of lung infection CF-370 in neutropenic
Slide 28: CF-370: Early-Stage Clinical Development Plan
CF-370: Early-Stage Clinical Development Plan Phase 1 Clinical Study Anticipated in Q2 2023 First-in-human Phase 1 SAD/MAD with BAL in healthy volunteers SAD: approximately 32 subjects, randomized 6:2 (CF-370:placebo) across four single ascending dose groups MAD: approximately 32 subjects, randomize
Slide 29: Direct Lytic Agents as Potential Countermeasures
Direct Lytic Agents as Potential Countermeasures BioDefense Agents for Biological Weapons
Slide 30: BioDefense Agents
BioDefense Agents Initial pathogenic targets Potential non-dilutive funding Several lead compounds with potent Funding may be available from a variety of activity against: government agencies (BARDA, NIH, USAMRDC and others) Burkholderia cepacia ContraFect has ongoing relationships with BARDA Yersin
Slide 31: ContraFect Corporate Information
ContraFect — Corporate Information
Slide 32: Financial Information
Financial Information Key Metrics September 30, 2022* Cash, cash equivalents and $17.6 million* marketable securities Total debt ―― Common shares outstanding 39.3 million *Cash, cash equivalents and marketable securities does not include approximately $6.2 million in net proceeds from our registered
Slide 33: Developing differentiated, first-in-class direct lytic agents
Developing differentiated, first-in-class direct lytic agents (DLAs) for life-threatening, drug-resistant infections NASDAQ: CFRX